Dragon Sail Pharmaceutical

Dragon Sail Pharmaceutical Co., Ltd. is a high-tech enterprise focusing on antibody drug CDMO services, and it is dedicated to providing one-stop services for partners from sequence to IND, clinical sample production to BLA and commercial production of antibody drugs.

Dragon Sail Pharmaceutical has built China’s first cross-contamination-free antibody production facility in Lin-gang Special Area of China (Shanghai) Pilot Free Trade Zone, with a total investment of RMB 690 million. The facility boasts a maximum drug substance production capacity of 12,000L, adheres to cGMP standards for China, the US, and Europe, and has passed EU QP audits.

Its unique NONCROS® cross-contamination-free antibody production platform supports compliant multi-product production lines with high operational efficiency and significant cost advantages. The company has established partnerships with over 100 biopharmaceutical companies worldwide, successfully delivering over 50 antibody protein projects, advancing 3 BLA projects, and is expected to achieve commercial project filings by the end of 2025.

Dragon Sail Pharmaceutical, headquartered in Shanghai, China, is a pioneering biopharmaceutical company committed to advancing health through cutting-edge technologies. With expertise in the development of monoclonal antibodies, bispecific antibodies, and fusion proteins, the company excels in addressing complex therapeutic challenges. Its state-of-the-art facilities and robust capabilities make it a trusted partner for global pharmaceutical and biotechnology companies.

Key Products and Services

• Biological Drugs: Monoclonal antibodies, bispecific antibodies, and fusion proteins.
• ADC Development: Expertise in antibody-drug conjugates.
• Custom Manufacturing: Scalable production solutions tailored to client needs.
• Research Support: Comprehensive R&D services for drug innovation.

Dragon Sail Pharmaceutical strives to create impactful medical solutions that enable faster and broader access to effective treatments. By combining innovation with operational excellence, the company is dedicated to fostering long-term partnerships and shaping the future of biopharmaceuticals.